Reddys Company Profile

What is the competitive landscape for REDDYS

REDDYS has three approved drugs.

Summary for Reddys

US Patents:	0
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Reddys

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Reddys	METOPROLOL SUCCINATE	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	078889-001	Aug 15, 2012	AB	RX	No	No
Reddys	DESLORATADINE	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	078367-002	Jul 12, 2010		RX	No	Yes
Reddys	DIVALPROEX SODIUM	divalproex sodium	TABLET, EXTENDED RELEASE;ORAL	090070-001	Mar 12, 2012	AB	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Reddys

Last updated: July 20, 2026

Reddy’s Pharmaceutical Competitive Landscape Analysis: Market Position, Strengths, and Strategic Insights

Executive summary: Dr. Reddy’s Laboratories has scaled globally across generics, branded generics, and select branded products, with ongoing IP and litigation discipline in the US and a manufacturing-driven cost position in oral solids and complex APIs. Its near-term competitive risk is concentrated in US oral generics where Paragraph IV pressure, settlement terms, and protracted switching dynamics can shorten late-cycle revenue windows. Strategic upside is concentrated in (i) portfolio rationalization toward higher-traffic molecules with multi-layer IP, (ii) lifecycle management via formulation and method-of-use defensibility, and (iii) accelerating capacity utilization in core manufacturing footprints while reducing dependency on single-plant bottlenecks.

Important: The requested topic is “Reddys” but the prompt does not specify which legal entity/product portfolio/drug (for example Dr. Reddy’s Laboratories, brand name drug, or specific NDA/ANDA). Without those identifiers, a complete competitive landscape analysis cannot be produced to a standard suitable for patent, litigation, Orange Book, exclusivity, or generic-entry risk work product.